We have an updated report [Version - 2024] available. Kindly sign up to get the sample of the report.
all report title image

MENA BIOLOGICS & BIOSIMILARS MARKET ANALYSIS

MENA Biologics & Biosimilars Market, By Product Type (Influenza Vaccines, Factor VIII ( Xyntha, Octanate, Kovaltry, Advate, Koate, Adynovate, Kogenate, Hemlibra, Elocta, Recombinate, Feiba, Immunate, Alphanate, Novoeight), Erythropoietin (Epoetin Alfa (Procrit, Epogen), Darbepoietin Alfa (Aranesp), Epoetin Alfa-epbx (Retacrit)), Aflibercept (EYLEA), and Ziv-Aflibercept (ZALTRAP))), By Therapeutic Application (Hemophilia, Age-related Macular Degeneration, Kidney Diseases, Influenza, and Others), By Geography (Gulf and Egypt)

  • Published In : Sep 2023
  • Code : CMI4393
  • Pages :160
  • Formats :
      Excel and PDF
  • Industry : Biotechnology

Regional Analysis

MENA Biologics & Biosimilars Market- Regional Analysis

Among region, the Gulf region is estimated to hold a dominant position in the MENA biologics & biosimilars market over the forecast period owing to increasing government initiatives for vaccination campaigns that boosts thesegment growth. For instance, on October 16, 2020, the Ministry of Health (Kuwait) launched a seasonal vaccination campaign for infectious diseases such as seasonal influenza and pneumococcal pneumonia.

  • Gulf: Saudi Arabia, UAE and Kuwait
  • Egypt
  • Need a Custom Report?

    We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

    Customize Now
    Logo

    Credibility and Certifications

    ESOMAR
    DUNS Registered
    Clutch
    DMCA Protected

    9001:2015

    Credibility and Certifications

    27001:2022

    Credibility and Certifications

    EXISTING CLIENTELE

    Joining thousands of companies around the world committed to making the Excellent Business Solutions.

    View All Our Clients
    trusted clients logo
    © 2024 Coherent Market Insights Pvt Ltd. All Rights Reserved.